FDA Approves Menveo in a New Single-Vial Presentation to Help Prevent Disease Caused by Meningococcal Bacteria Serogroups A, C, Y, and W

Single-vial presentation option removes the need for reconstitution of Menveo before use in individuals 10 through 55 years of age. 17 October 2022 -- GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA)...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news